(Q53538133)

English

Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.

scientific article published on 8 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

visceral leishmaniasis

1 reference

based on heuristic

1 reference

based on heuristic

Rajesh Ravindran

2

object named as

Rajesh Ravindran

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

author name string

Sudipta Bhowmick

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

Nahid Ali

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

language of work or name

0 references

publication date

8 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

25

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

35

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

6544-6556

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Visceral leishmaniasis control: a public health perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Recent advances in vaccines for leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Cytokine patterns in the pathogenesis of human leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Clinical and experimental advances in treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Advances in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Leishmania vaccines: progress and problems.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Second-generation vaccines against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cellsin vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

The relationship of IL-4- and IFNγ-producing T cells studied by lineage ablation of IL-4-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Interaction of positively-charged liposomes with blood: implications for their application in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Recombinant interleukin 12 cures mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

Silver staining of proteins in polyacrylamide gels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism and regulation of immunoglobulin isotype switching.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.05.042

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

release_slhvh4yizjewbehbrnpvhhekei

1 reference

https://api.fatcat.wiki/v0/release/slhvh4yizjewbehbrnpvhhekei

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17655984

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53538133&oldid=1842999986"